Abdul Khalifeh

Contributor

tags:   Antibiotic resistance     Artificial Intelligence     Big Data     Biologics     Biopharma news     Blockchain     COVID-19     CROs     Healthcare     Pharmaceutical industry trends     R&D Outsourcing     Upcoming Events     Natural Products     Pharma 4.0 (Digital Tech and Data Analytics)     Pharma R&D Outsourcing     Vaccine Development    

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Posts by this author

Pharmapack Europe 2021 Award Winners Announced

   53
Pharmapack Europe 2021 Award Winners Announced

Pharmapack Europe recognizes excellence and innovation in connected devices, wearables, packaging, sustainability, eco-design, patient-centric design, and animal health

Pharmapack Europe: Innovation, Networking and Education

   189
Pharmapack Europe: Innovation, Networking and Education

Welcome to Pharmapack Europe 2021!

It is an extremely exciting time for the pharmaceutical drug delivery and packaging industry as we emerge from the pandemic driven forward by renewed emphasis on innovation, sustainable supply chains & speeding products to market. The inspiration of everything the industry has achieved in developing new vaccines and therapies is fuelling a surge in new development – from autoinjectors and transdermal patches, to smart packaging, sustainability and patient centricity.

WuXi STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland

   201
WuXi STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland

New York & Shanghai, 3rd August, 2021: WuXi STA – a subsidiary of WuXi AppTec –  today announced that it has completed the acquisition of a drug product manufacturing facility in Couvet, Switzerland from Bristol Myers Squibb (NYSE: BMY). WuXi STA first announced its plans to purchase the facility earlier this year. The acquisition will enhance WuXi STA’s capabilities by adding capacity to support its global partners in bringing innovative medicines to patients around the world.